Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies
Authors
Keywords
-
Journal
Cells
Volume 8, Issue 1, Pages 31
Publisher
MDPI AG
Online
2019-01-10
DOI
10.3390/cells8010031
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Forkhead box C1 promotes colorectal cancer metastasis through transactivating ITGA7 and FGFR4 expression
- (2018) Jian Liu et al. ONCOGENE
- FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression
- (2018) Xiangdong Zhao et al. MOLECULAR CARCINOGENESIS
- Making way for suppressing the FGF19/FGFR4 axis in cancer
- (2018) Nestor Prieto-Dominguez et al. Future Medicinal Chemistry
- FGF19 amplification reveals an oncogenic dependency upon autocrine FGF19/FGFR4 signaling in head and neck squamous cell carcinoma
- (2018) Lixia Gao et al. ONCOGENE
- FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
- (2017) Lixia Gao et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report
- (2017) Lixia Gao et al. CELLULAR ONCOLOGY
- FGF19 genetic amplification as a potential therapeutic target in lung squamous cell carcinomas
- (2017) Xiaochen Zhang et al. Thoracic Cancer
- Abstract 3852: U3-1784, a human anti-FGFR4 antibody for the treatment of cancer
- (2016) Rene Bartz et al. CANCER RESEARCH
- First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation
- (2016) R. Kim et al. EUROPEAN JOURNAL OF CANCER
- Stapled peptides: providing the best of both worlds in drug development
- (2016) Xiayang Xie et al. Future Medicinal Chemistry
- A New Method to Study Heterodimerization of Membrane Proteins and Its Application to Fibroblast Growth Factor Receptors
- (2016) Nuala Del Piccolo et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival
- (2016) Kai Hung Tiong et al. Oncotarget
- Up-regulation of fibroblast growth factor 19 and its receptor associates with progression from fatty liver to hepatocellular carcinoma
- (2016) Yan Li et al. Oncotarget
- A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment
- (2015) Maria E. Cabanillas et al. CANCER
- Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications
- (2015) Teresa Helsten et al. CANCER AND METASTASIS REVIEWS
- Targeting FGFR Signaling in Cancer
- (2015) M. Touat et al. CLINICAL CANCER RESEARCH
- The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
- (2015) T. Helsten et al. CLINICAL CANCER RESEARCH
- Targeting FGF19 binding to its receptor system: A novel therapeutic approach for hepatocellular carcinoma
- (2015) Nadia Panera et al. HEPATOLOGY
- Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?
- (2015) Jakob Paur et al. HEPATOLOGY
- Quantitative Proteomic Verification of Membrane Proteins as Potential Therapeutic Targets Located in the 11q13 Amplicon in Cancers
- (2015) Heather Hoover et al. JOURNAL OF PROTEOME RESEARCH
- Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23
- (2015) Chiara Degirolamo et al. NATURE REVIEWS DRUG DISCOVERY
- Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer
- (2015) LINGLING HU et al. ONCOLOGY REPORTS
- FGFR4 Is a Potential Predictive Biomarker in Oral and Oropharyngeal Squamous Cell Carcinoma
- (2015) Koos Koole et al. PATHOBIOLOGY
- Frequent methylation of the KLOTHO gene and overexpression of the FGFR4 receptor in invasive ductal carcinoma of the breast
- (2015) Ashraf Dallol et al. TUMOR BIOLOGY
- First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
- (2015) M. Hagel et al. Cancer Discovery
- FGF19 promotes epithelial-mesenchymal transition in hepatocellular carcinoma cells by modulating the GSK3β/β- catenin signaling cascade via FGFR4 activation
- (2015) Huakan Zhao et al. Oncotarget
- Abstract CT215: A phase I trial of LY2874455, a fibroblast growth factor receptor inhibitor, in patients with advanced cance
- (2015) Jeanne Tie et al. CANCER RESEARCH
- Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
- (2014) Christine Heinzle et al. CURRENT PHARMACEUTICAL DESIGN
- Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors
- (2014) Li Tan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer
- (2014) R C Turkington et al. Cell Death & Disease
- Drug Resistance in Cancer: An Overview
- (2014) Genevieve Housman et al. Cancers
- Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
- (2013) R. Dienstmann et al. ANNALS OF ONCOLOGY
- FGFR4 Role in Epithelial-Mesenchymal Transition and Its Therapeutic Value in Colorectal Cancer
- (2013) Alberto Peláez-García et al. PLoS One
- Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534)
- (2013) Samuel Q. Li et al. PLoS One
- Fibroblast Growth Factor Receptor Inhibitors as a Cancer Treatment: From a Biologic Rationale to Medical Perspectives
- (2013) Maria Vittoria Dieci et al. Cancer Discovery
- Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma
- (2012) Seiki Miura et al. BMC CANCER
- Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth
- (2012) Hannah van Malenstein et al. CANCER LETTERS
- Abstract LB-122: A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors
- (2012) J. Wolf et al. CANCER RESEARCH
- AZD4547: An Orally Bioavailable, Potent, and Selective Inhibitor of the Fibroblast Growth Factor Receptor Tyrosine Kinase Family
- (2012) P. R. Gavine et al. CANCER RESEARCH
- Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib
- (2012) A. Villanueva et al. CLINICAL CANCER RESEARCH
- Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening
- (2011) Eric T. Sawey et al. CANCER CELL
- Tumor Metastasis: Molecular Insights and Evolving Paradigms
- (2011) Scott Valastyan et al. CELL
- NADPH oxidase-dependent oxidative stress in the failing heart: From pathogenic roles to therapeutic approach
- (2011) Yanti Octavia et al. FREE RADICAL BIOLOGY AND MEDICINE
- FGF19 Regulates Cell Proliferation, Glucose and Bile Acid Metabolism via FGFR4-Dependent and Independent Pathways
- (2011) Ai-Luen Wu et al. PLoS One
- FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis
- (2011) S. Kir et al. SCIENCE
- Resistance to Chemotherapy Is Associated with Fibroblast Growth Factor Receptor 4 Up-Regulation
- (2009) A. Roidl et al. CLINICAL CANCER RESEARCH
- The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells
- (2009) A Roidl et al. ONCOGENE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More